You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
Kedrion Biosc - Front Image


  1. 31-03-2017

    Annual Results 2016

    Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%

    read more 
  2. 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  3. 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.

    read more 
  4. 12-11-2014

    Kedrion joins the programme “ELITE for Large Corporates”

    Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

    read more 
  5. 15-10-2014

    New generation immunoglobulins: in January production of clinical batches

    The first batch for the feasibility test was produced at the Gödöllő plant in September with results in compliance with specifications

    read more 
  6. 08-09-2014

    Kedrion’s key financials and milestones in the new Investor Relations area

    Website area dedicated to providing the financial community with latest information regarding the Kedrion Bond

    read more 
  7. 09-09-2014

    Bond marked by Wide Distribution

    The success of the operation is reflected in the wide variety of investors involved

    read more 
  8. 09-09-2014

    Issuance of Kedrion Bond a success

    The issuance took place after a three-day European road-show in London, Paris and Milan

    read more 


For more information please contact: [email protected]